

## Young researchers recognised at Magstim TMS Summer School 2008

Magstim has announced the winners of both the Magstim Young Investigator Award 2008 and the Summer School Poster Session during the first day of the Magstim Transcranial Magnetic Stimulation (TMS) Summer School 2008, held in London on 30th – 31st May. Both awards recognise the scientific research of those working with magnetic stimulation within the fields of Neuroscience and Neurology.

Dr Marco Davare, University College London (UCL), Institute of Neurology, Sobell Dept of Motor Neuroscience and Movement Disorders has been awarded the Magstim

Young Investigator Award 2008 for his work studying how the brain controls skilled hand movements.

PhD student Niamh Kennedy, Queen's University Belfast, School of Psychology was awarded the Poster Prize for her Poster on the effect of simultaneous contractions of ipsilateral muscles on changes in corticospinal excitability induced by paired associative stimulation (PAS).

For more information contact:

Catherine Stormont,  
Tel. +44 (0)1489 557672,  
Email. catherines@alto-marketing.com



From left to right: Magstim Young Investigator Award winner Dr Marco Davare with Professor Vince Walsh, Dr Heidi Johansen-Berg, and Poster Prize winner Niamh Kennedy.

## News Review

### ReQuip XL® - a new once daily formulation for the treatment of Parkinson's disease

GlaxoSmithKline (GSK) have launched a new treatment for Parkinson's disease (PD) in the UK. ReQuip XL® (ropinirole prolonged-release tablets) is the UK's first and only once-daily non-ergot oral dopamine agonist available for the treatment of PD, providing continuous delivery of ropinirole from a single daily dose.

Ropinirole prolonged-release is approved for the treatment of idiopathic Parkinson's disease (Monotherapy and Adjunct Therapy) in patients already taking ropinirole immediate release tablets and in whom adequate symptomatic control has been established.

Although a number of therapies are available for the treatment of PD, interim results from a recent pan-European survey of 1,026 people conducted by the European Parkinson's Disease Association (EPDA) suggest that there is still a significant unmet need for the treatment of PD.

The clinical trials programme has demonstrated that ropinirole prolonged-release tablets are an effective agent, generally well-tolerated in the treatment of both early- and advanced stage PD.

GSK has developed the ReQuip Patient




Support Service (RPSS) to offer patients free guidance and support should they decide with their healthcare professional to switch from ropinirole 3x-daily to ropinirole prolonged-release. The RPSS is designed to complement the care provided by their NHS health professionals. The service comprises proactive telephone calls over a three-month period from trained health professionals (including nurses) to patients starting ropinirole prolonged-release tablets, to help ensure a smooth transition from ropinirole 3x-daily to ropinirole prolonged-release.

For further information contact  
GlaxoSmithKline UK on  
Tel. 020 8990 2144.

### The new A1 series from Nikon

Even the most rapid biological processes can now be captured at ultra high resolution as a result of the launch of a new range of confocal laser scanner systems by Nikon Instruments. Two models are available; the fully automated A1 and the high specification A1R. The A1 utilises conventional paired galvanometers producing high resolution images (up to 4096 x 4096 pixels), whilst the A1R incorporates a unique hybrid scanner system (offering frame rates of 30fps, 512 x 512 pixels). This facilitates ultra-high-speed imaging with unsurpassed image quality. Furthermore, the hybrid scanner enables simultaneous photo-activation and imaging, critical for unveiling cell dynamics and interactions.



The new systems are a natural complement to the recently launched Ti inverted microscope, particularly when coupled with Nikon's patented Perfect Focus System, essential for eliminating focus drift. Together they set a new standard for advanced time-lapse studies of rapid cellular interactions to literally bring biological imaging to life.

For more information please contact  
Nikon Instruments Europe, Tel. 0208 247 1718,  
Email. info@nikoninstruments.eu  
Web. www.nikoninstruments.eu

### Best practice recommendations for young people with cerebral palsy in transition

The experience of young disabled people with cerebral palsy and other long-term neurological conditions, moving from children's to adult health services can often be traumatic, and in many health settings there is a gap in service provision. To address this 'gap', best practice recommendations entitled 'Young People with Cerebral Palsy in Transition from Paediatric to Adult Health Services: Best Practice Recommendations' have been launched this month aimed at all health professionals who are involved in the transition of care of the young person with cerebral palsy.



Mr Richard Parnell, Head of Research at the national disability organisation, Scope said: "Transfer of care and support from the paediatric service to the adult health service is a major step in these young people's lives and it needs to be holistic, taking into consideration all transition issues, not just health. Scope welcomes this document and hopes that health professionals will review transition service provision in their own hospitals".

Further information contact: Ipsen Ltd,  
Tel. 01753 627609  
Email. access.coordinator@ipsen.com